Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database
Open Access
- 26 March 2013
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (10) , 901-905
Abstract
Aim: To compare ‘progression to insulin’ for three cohorts on oral antidiabetic medication combinations: metformin/sulphonylurea (Met/ SU ), metformin/thiazolidinedione (Met/ TZD ) and sulphonylurea/thiazolidinedione ( SU / TZD ). Methods: Retrospective cohort analysis design was used. The subjects were US nationwide members of military and their families. A total of 5608 patients who were on antidiabetic monotherapy for at least 1 year before adding a second agent to their medication regimen between October 2001 and September 2008 participated in this study. Mean age ranged from 64 to 71 years among the cohorts. Cox regression compared the progression to insulin, adjusting for demographics, months of follow‐up and co‐morbidities [measured with Chronic Disease Score (CDS)]. Results: By the end of the 2‐ to 6‐year follow‐up period, 14.3% of the Met/ TZD cohort, 23.6% of the Met/ SU cohort and 28.2% of the SU / TZD cohort had insulin added to their regimen. Those in the Met/ SU cohort had a 1.8 times higher probability of progression to insulin than those in the Met/ TZD cohort [odds ratio ( OR ) = 1.80, 95% confidence interval ( CI ) = 1.51–2.14), and those in the SU / TZD cohort had a 2.5 times higher probability of progression to insulin than those in the Met/ TZD cohort ( OR = 2.51, 95% CI = 2.04–3.08). Conclusion: When sensitizers were paired (Met/ TZD ), a lower percentage of patients progressed to insulin during the study period, as opposed to patients who used a combination of a secretagogue with a sensitizer ( SU / TZD or Met/ SU ).Keywords
This publication has 23 references indexed in Scilit:
- Initial Sulfonylurea Use and Subsequent Insulin Therapy in Older Subjects with Type 2 Diabetes MellitusDiabetes Therapy, 2012
- Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetesDiabetes & Metabolism, 2010
- Economic Costs of Diabetes in the U.S. in 2007Diabetes Care, 2008
- Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UKPharmacoEconomics, 2006
- Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in GermanyPharmacoEconomics, 2006
- Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in SpainPharmacoEconomics, 2006
- Long‐term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetesDiabetes, Obesity and Metabolism, 2005
- Secondary Failure Rates Associated with Metformin and Sulfonylurea Therapy for Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesDiabetologia, 2005
- Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population‐based studyDiabetic Medicine, 2002